At the early stages of drug development, sponsors may not have a final finished combination product configuration in mind and may rely on standalone devices (syringes, infusion pumps, etc.,) or more simple presentations (pre-filled syringes) to support early-phase clinical studies. As a result, there may be challenges when sponsors want to bridge to more complex commercial presentations and have to meet new evidence expectations from the agency. Therefore, how do you select your investigational device(s)? What are critical clinical or device design considerations to enable a successful bridging approach and commercial final finished combination product? This panel will explore regulatory and technical expectations for investigational delivery devices at each phase, and how sponsors can prepare a strong development and bridging approach to support their final commercial presentation.